Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
VERA

VERA - Vera Therapeutics, Inc. Stock Price, Fair Value and News

35.98USD-1.42 (-3.80%)Market Closed

Market Summary

VERA
USD35.98-1.42
Market Closed
-3.80%

VERA Alerts

  • 1 major insider sales recently.

VERA Stock Price

View Fullscreen

VERA RSI Chart

VERA Valuation

Market Cap

2.0B

Price/Earnings (Trailing)

-20.87

EV/EBITDA

-20.26

Price/Free Cashflow

-19.72

MarketCap/EBT

-20.5

VERA Price/Earnings (Trailing)

VERA Profitability

Return on Equity

-26.67%

Return on Assets

-22.49%

Free Cashflow Yield

-5.07%

VERA Fundamentals

VERA Earnings

Earnings (TTM)

-94.3M

Earnings Growth (Yr)

5.61%

Earnings Growth (Qtr)

-10.63%

Breaking Down VERA Revenue

Last 7 days

-6.5%

Last 30 days

-15.7%

Last 90 days

-16.8%

Trailing 12 Months

182.9%

How does VERA drawdown profile look like?

VERA Financial Health

Current Ratio

28.63

Debt/Equity

0.14

Debt/Cashflow

-1.99

VERA Investor Care

Shares Dilution (1Y)

23.59%

Diluted EPS (TTM)

-2.03

Tracking the Latest Insider Buys and Sells of Vera Therapeutics, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
May 16, 2024
young joseph r
acquired
325,047
7.87
41,302
svp, finance, chief acct offcr
May 16, 2024
young joseph r
sold
-1,747,780
42.3171
-41,302
svp, finance, chief acct offcr
May 15, 2024
young joseph r
acquired
64,774
3.9396
16,442
svp, finance, chief acct offcr
May 15, 2024
young joseph r
sold
-861,092
42.2684
-20,372
svp, finance, chief acct offcr
Apr 10, 2024
young joseph r
sold
-228,560
40.00
-5,714
svp, finance, chief acct offcr
Apr 03, 2024
grant sean
acquired
1,484,440
14.87
99,828
chief financial officer

1–10 of 50

Which funds bought or sold VERA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 30, 2024
CAMBRIDGE TRUST CO
added
386
1,922,310
2,074,370
0.08%
May 24, 2024
Cetera Investment Advisers
new
-
248,587
248,587
-%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
96.71
357,245
436,245
0.06%
May 20, 2024
Virtu Financial LLC
new
-
375,000
375,000
0.03%
May 17, 2024
Artal Group S.A.
new
-
21,819,500
21,819,500
0.56%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
added
18.66
975,892
1,395,320
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
2,575,940
2,575,940
-%
May 16, 2024
COMERICA BANK
new
-
2,070
2,070
-%
May 15, 2024
TWO SIGMA ADVISERS, LP
new
-
2,604,450
2,604,450
0.01%
May 15, 2024
MARSHALL WACE, LLP
new
-
20,720,000
20,720,000
0.03%

1–10 of 42

Are Funds Buying or Selling VERA?

Are funds buying VERA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VERA
No. of Funds

Unveiling Vera Therapeutics, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 26, 2024
sofinnova venture partners x, l.p.
5.3%
2,793,987
SC 13D/A
Feb 20, 2024
sofinnova venture partners x, l.p.
6.9%
3,628,446
SC 13D/A
Feb 14, 2024
commodore capital lp
12.3%
5,450,000
SC 13G/A
Feb 14, 2024
commodore capital lp
11.3%
5,001,783
SC 13G/A
Feb 14, 2024
kynam capital management, lp
8.22%
3,650,339
SC 13G/A
Feb 14, 2024
ares trading s.a.
3.6%
1,913,501
SC 13G/A
Feb 14, 2024
citadel advisors llc
0.0%
6
SC 13G/A
Feb 12, 2024
woodline partners lp
2.2%
1,140,632
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 05, 2024
longitude capital partners iv, llc
6.5%
3,429,927
SC 13D/A

Recent SEC filings of Vera Therapeutics, Inc.

View All Filings
Date Filed Form Type Document
Jun 12, 2024
8-K
Current Report
Jun 11, 2024
3
Insider Trading
Jun 11, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading
May 17, 2024
4
Insider Trading

Peers (Alternatives to Vera Therapeutics, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Vera Therapeutics, Inc. News

Latest updates
Defense World12 hours ago
MarketBeat13 Jun 202404:12 pm

Vera Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets138.9%41917617619521013113114916584.0091.0098.0052.0055.005.00
  Current Assets142.0%41617217219120412612514215883.0090.0096.0052.0054.004.00
    Cash Equivalents51.3%69.0046.0027.0034.0013844.0031.0051.0011280.0086.0092.0050.0054.004.00
  Net PPE-12.0%0.000.000.000.000.000.000.000.000.00-----1.00
Liabilities-10.9%66.0074.0052.0055.0052.0055.0026.0027.0031.0014.006.005.006.004.002.00
  Current Liabilities-34.8%15.0022.0025.0027.0024.0026.0016.0017.0020.008.004.004.004.002.001.00
  Long Term Debt0.4%50.0050.0025.0025.0025.0025.005.005.005.005.00-----
Shareholder's Equity247.7%35410212414115877.0010612213470.0085.0092.00---
  Retained Earnings-9.2%-337-309-283-263-243-213-180-155-141-124-107-99.60-96.16-91.45-38.03
  Additional Paid-In Capital68.4%6914104074044012902872782761941931923.002.001.00
Shares Outstanding19.4%51.0043.0042.0044.0038.0027.0026.0026.0024.0013.0021.0010.00-0.000.00
Float----449---163---94.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q4
Cashflow From Operations-34.5%-33,830-25,144-22,973-17,772-26,292-21,162-18,420-19,033-8,981-6,438-5,484-7,665-4,121-27,382-2,447-2,675-2,305-
  Share Based Compensation28.0%4,1243,2212,9232,6822,6672,7482,4522,0251,66296293371340414311611.0061.00-
Cashflow From Investing-1281.8%-219,28618,55616,228-86,44912,23413,437-2,440-42,094-39,455-5,000-796-57.00--47.00-52.00-
Cashflow From Financing1013.8%276,54024,828297432107,98420,70990848.0080,2684,921-48,989-28.0079,801-94.006164,967-
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VERA Income Statement

2024-03-31
Condensed Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development$ 23,200$ 25,108
General and administrative7,9126,150
Total operating expenses31,11231,258
Loss from operations(31,112)(31,258)
Other income (expense):  
Interest income4,1861,623
Interest expense(1,906)(874)
Other income453441
Change in fair value of non-marketable equity securities(4)(1)
Total other income2,7291,189
Net loss(28,383)(30,069)
Other comprehensive income (loss):  
Change in unrealized (loss) gain on marketable securities(424)220
Comprehensive loss$ (28,807)$ (29,849)
Net loss per share attributable to common stockholders, basic$ (0.56)$ (0.8)
Net loss per share attributable to common stockholders, diluted$ (0.56)$ (0.8)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic50,971,93337,667,566
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted50,971,93337,667,566

VERA Balance Sheet

2024-03-31
Condensed Balance Sheet - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 69,105$ 45,681
Marketable securities334,559115,035
Prepaid expenses and other assets, current12,70611,307
Total current assets416,370172,023
Property and equipment, net8192
Operating lease right-of-use assets2,4322,949
Prepaid expenses and other assets, noncurrent473482
Total assets419,356175,546
Current liabilities:  
Accounts payable5,20911,118
Operating lease liabilities2,2752,436
Accrued expenses and other liabilities, current7,0598,749
Total current liabilities14,54322,303
Long-term debt50,06649,877
Operating lease liabilities, noncurrent9191,395
Accrued expenses and other liabilities, noncurrent286286
Total liabilities65,81473,861
Stockholders' equity  
Preferred stock, $0.001 par value; 10,000,000 authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 202300
Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 54,457,371 and 44,452,161 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively5444
Additional paid-in capital691,146410,492
Accumulated other comprehensive income (loss)(173)251
Accumulated deficit(337,485)(309,102)
Total stockholders' equity353,542101,685
Total liabilities and stockholders' equity$ 419,356$ 175,546
VERA
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
 CEO
 WEBSITEhttps://veratx.com
 INDUSTRYBiotechnology
 EMPLOYEES49

Vera Therapeutics, Inc. Frequently Asked Questions


What is the ticker symbol for Vera Therapeutics, Inc.? What does VERA stand for in stocks?

VERA is the stock ticker symbol of Vera Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vera Therapeutics, Inc. (VERA)?

As of Fri Jun 14 2024, market cap of Vera Therapeutics, Inc. is 1.97 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VERA stock?

You can check VERA's fair value in chart for subscribers.

What is the fair value of VERA stock?

You can check VERA's fair value in chart for subscribers. The fair value of Vera Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vera Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VERA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vera Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether VERA is over valued or under valued. Whether Vera Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Vera Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VERA.